Moleculin Biotech (MBRX) Expected to Announce Quarterly Earnings on Friday

Moleculin Biotech (NASDAQ:MBRX) will likely be issuing its quarterly earnings data before the market opens on Friday, March 21st. Analysts expect the company to announce earnings of ($1.25) per share for the quarter.

Moleculin Biotech Stock Performance

Shares of NASDAQ:MBRX traded up $0.05 on Thursday, hitting $1.09. The company’s stock had a trading volume of 450,901 shares, compared to its average volume of 1,396,512. The company has a 50-day simple moving average of $1.38 and a 200 day simple moving average of $2.04. Moleculin Biotech has a 1 year low of $0.40 and a 1 year high of $7.80.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. StockNews.com initiated coverage on Moleculin Biotech in a research note on Thursday, March 13th. They set a “sell” rating for the company. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Moleculin Biotech in a report on Monday, March 3rd. Finally, Maxim Group lowered shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.